TrialClinical pharmacology in drug development2016

Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.

Veit J Erpenbeck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.